Additionally, MET expression is able to activate CD4+ T cells and can induce tumor cell killing in natural killer/T-cell lymphoma cell lines, in which MET elicits an anti-tumor immune response by increasing the activation of T cells and reducing the synthesis of TGF-beta [39]. Here, MET is linked to T-cell non-Hodgkin lymphoma.